Δ10-19[R8A]GeXIVA

General Information


DRACP ID  DRACP06237

Peptide Name   Δ10-19[R8A]GeXIVA

Sequence  RSPYDRRARY

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides α9α10nAChR inhibitor



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  α9α10nAChR

Affinity  Not available

Mechanism  Specifically block the α9α10nAChR

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C57H90N22O16

Absent amino acids  CEFGHIKLMNQTVW

Common amino acids  R

Mass  150017

Pl  11.14

Basic residues  4

Acidic residues  1

Hydrophobic residues  1

Net charge  3

Boman Index  -7027

Hydrophobicity  -247

Aliphatic Index  10

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  2980

Absorbance 280nm  331.11

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID CN112010969A

Patent Title  Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.